A novel sustained-release formulation of buprenorphine (CAM2038) blocked the euphoric effects of illicit opioids and suppressed withdrawal in patients with opioid use disorder (OUD), according to a study published in JAMA Psychiatry. Weekly subcutaneous buprenorphine injections may prevent the misuse, diversion, and nonadherence associated with the current daily sublingual buprenorphine formulation, wrote the researchers.